Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta

Journal of Neurology

Volumn 251, Issue 12, 2004, Pages 1502-1506

  Patti, Francesco ^a   Reggio, Ester ^a   Palermo, Filippo ^b   Fiorilla, Teresa ^a   Politi, Guido ^b   Nicoletti, Alessandra ^a   Reggio, Arturo ^a  

^a Department of Neurological Sciences ^*  (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Cyclophosphamide; Follow up; Interferon beta; Multiple sclerosis; Stabilization

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; INTERFERON BETA SERINE;

ADENOMA; ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENCE RISK; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ADJUVANTS, IMMUNOLOGIC; ADULT; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 12844251832     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-004-0581-2     Document Type: Article

References (26)

1. Carter JL, Hafler DA, Dawson DM, Orav J, Weiner HL (1988) Immunosuppression with high-dose IV cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-years experience in 164 patients. Neurology 38:9-14
2. Edan G, Miller D, Clanet C, Confavreux C, Lyon-Caen O, Lubetzki C, Brochet B, Berry I, Rolland Y, Froment JC, Dousset V, Cabanis E, Iba-Zizen MT, Gandon JM, Lai HM, Moseley I, Sabouraund O (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicenter study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112-118
3. Giovannoni G, Munschauer FE, Deisenhammer F (2002) Neutralising antibodies anti interferon beta during treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 73:465-469
4. Gobbini MI, Smith ME, Richert ND, Frank JA, Mc Farland HF (1999) Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmunol 99:142-149
5. Gonsette R, Demonty L, Delmonte P (1977) Intensive immunosuppression with cyclophosphamide in multiple sclerosis: follow-up of 110 patients for 2-6 years. J Neuroimunol 214:173-181
6. Goodkin DE, Plencer S, Palmer SJ, Teetzen M, Hartsgaard D (1987) Cyclophosphamide in chronic progressive multiple sclerosis: maintenance vs non maintenance therapy. Arch Neurol 44:823-827; Group Neurology 43: 910-908
7. Goodkin DE, Plencer S, Palmer SJ, Teetzen M, Hartsgaard D (1987) Cyclophosphamide in chronic progressive multiple sclerosis: maintenance vs non maintenance therapy. Arch Neurol 44:823-827; Group Neurology 43: 910-908
8. Hafler DA, Weiner HL (1995) Immunological mechanisms and therapy in multiple sclerosis. Immunol Rev 144: 75-107
9. Hauser S, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, Mills JA, Weiner HL (1983) Intensive immunosuppression in progressive multiple sclerosis: a randomised, three-arm study of high dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med 308(4): 173-180
10. Hommes OR, Lamers KJB, Reekers P (1980) Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis. J Neurol 223:177-190
11. Kahn OA, Zvartau-Hind M, Caon C, Din MU, Cochran M, Lisak D, Tselis AC, Kamholz JA, Garben JV, Lisak RP (2001) Effects of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler 7:185-188
12. Kallen B, Dohlsten M, Klementsson H (1986/1992) Effect of cyclophosphamide pretreatment on autoimmune encephalomyelitis in rats. Acta Neurol Scand 73(4):338-344; PMID: 3727911. J Neuroimmunol 39(3):201-210
13. Kallen B, Dohlsten M, Klementsson H (1986/1992) Effect of cyclophosphamide pretreatment on autoimmune encephalomyelitis in rats. Acta Neurol Scand 73(4):338-344; PMID: 3727911. J Neuroimmunol 39(3):201-210
14. Karussis DM, Slavin S, Ben-Nun A, Ovadia H, Vourka-Karussis U, Lehmann D, Mizrachi-Kol R, Abramsky O (1992) Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation. J Neuroimmunol 39(3):201-210
15. Martin R, Mc Farland HF, Mc Farland DE (1992) Immunological aspects of demyelinating diseases. Ann Rev Immunol 10:153-187
16. Minagawa H, Takenaka A, Itoyama Y, Mori R (1987) Experimental allergic encephalomyelitis in the Lewis rat. A model of predictable relapse by cyclophosphamide. J Neurol Sci 78(2): 225-35
17. Ormerod IE, Miller DH, Mc Donald WI, et al. (1988) The role of MRI imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain 110: 1579-1616
18. Paterson PY, Drobish DG (1969) Cyclophosphamide: effects on experimental allergic encephalomyelitis in Lewis rats. Science 165:191-192
19. Patti F, Cataldi ML, Nicoletti F, Reggio E, Nicoletti A, Reggio A (2001) Combination of cyclophosphamide and interferon-β halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosurg Psychiatry 71:404-407
20. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13(3):227-231
21. The Canadian cooperative trial of cyclophosphamide and plasma-exchange in progressive multiple sclerosis (1991) The Canadian Cooperative Multiple Sclerosis Study Group. Lancet 39: 1143-1149
22. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338(5):278-285
23. Weiner HL, Cohen JA (2002) Treatment of multiple sclerosis with cyclophosphamide: critical review and immunologic effects. Mult Scler 8(2): 142-154
24. Weiner HL, Mackin GA, Orav J, Hafler DA, Dawson DM, La Pierre Y, Herndon R, Lehrich JR, Hauser SL, Truel A, et al. (1987) Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment. Neurology 43:900-908
25. Weinstock-Guttman B, Kinkel RP, Cohen JA, et al. (1997) Treatment of "transitional MS" with cyclophosphamide and methyl-prednisolone (CTX-MP) followed by interferon-β (abstract). Neurology 48:(Suppl 2): A341
26. Weinstock-Guttman B, Kinkel RP, Cohen JA, Ransohoff RM, Schwetz KK, Gogol D, Namey M, Rudick RA (1997) Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. Neurologist 3:178-185